A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 05 02 2024
accepted: 14 05 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: aheadofprint

Résumé

Escherichia coli can cause infections in the urinary tract and in normally sterile body sites leading to invasive E. coli disease (IED), including bacteraemia and sepsis, with older populations at increased risk. We aimed to estimate the theoretical coverage rate by the ExPEC4V and 9V vaccine candidates. In addition, we aimed at better understanding the diversity of E. coli isolates, including their genetic and phenotypic antimicrobial resistance (AMR), sequence types (STs), O-serotypes and the bacterial population structure. Blood and urine culture E. coli isolates (n = 304) were collected from hospitalized patients ≥60 years (n = 238) with IED during a multicentric, observational study across three continents. All isolates were tested for antimicrobial susceptibility, O-serotyped, whole-genome sequenced and bioinformatically analysed. A large diversity of STs and of O-serotypes were identified across all centres, with O25b-ST131, O6-ST73 and O1-ST95 being the most prevalent types. A total of 45.4% and 64.7% of all isolates were found to have an O-serotype covered by the ExPEC4V and ExPEC9V vaccine candidates, respectively. The overall frequency of MDR was 37.4% and ST131 was predominant among MDR isolates. Low in-patient genetic variability was observed in cases where multiple isolates were collected from the same patient. Our results highlight the predominance of MDR O25b-ST131 E. coli isolates across diverse geographic areas. These findings provide further baseline data on the theoretical coverage of novel vaccines targeting E. coli associated with IED in older adults and their associated AMR levels.

Identifiants

pubmed: 39001716
pii: 7713240
doi: 10.1093/jac/dkae182
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : University Medical Center Utrecht
Organisme : European Federation of Pharmaceutical Industries and Associations
Organisme : Innovative Medicines Initiative Joint Undertaking
ID : 115523
Organisme : European Union Seventh Framework Program
ID : FP7/2007-2013
Organisme : UMC Utrecht
Organisme : Janssen Research & Development

Investigateurs

Gert Leten (G)
Sofie Van Mieghem (S)
Madison Violette (M)
Sonal Munshi (S)
Moussa Aitabi (M)
Anna Maria Azzini (AM)
Elda Righi (E)
Nicola Duccio Salerno (ND)
Giuliana Lo Cascio (GL)
Eleonora Cremonini (E)
Álvaro Pascual (Á)
Reinaldo Espíndola (R)
Virginia Palomo (V)
Olivier Barraud (O)
Sarah V Walker (SV)
Naomi Akai (N)
Risa Kimura (R)
Louis Lakatos (L)
Killian De Blacam (K)
Joshua Thaden (J)
Felicia Ruffin (F)
Michael Dagher (M)

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Auteurs

Enya Arconada Nuin (E)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Tuba Vilken (T)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Basil Britto Xavier (BB)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Department of Medical Microbiology and Infection Control, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Joachim Doua (J)

Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium.

Brian Morrow (B)

Janssen Research & Development, Raritan, NJ, USA.

Jeroen Geurtsen (J)

Bacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Oscar Go (O)

Janssen Research & Development, Raritan, NJ, USA.

Bart Spiessens (B)

Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium.

Michal Sarnecki (M)

Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland.

Jan Poolman (J)

Bacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.

Marc Bonten (M)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
ECRAID, Utrecht, The Netherlands.

Miquel Ekkelenkamp (M)

Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Christine Lammens (C)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Herman Goossens (H)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Youri Glupczynski (Y)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.

Sandra Van Puyvelde (S)

Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.

Classifications MeSH